ADHD Research Today is a free monthly online journal that collates and summarizes the latest research about ADHD, including details on attention-deficit hyperactivity disorder, drugs, treatment, symptoms.

A possible antienuretic effect of reboxetine in children and adolescents with attention deficit/hyperactivity disorder: case series.

Toren P, Ratner S, Laor N, Lerer-Amisar D, Weizman A

Tel Aviv-Brull Community Mental Health Center, 1 Geiger Street, Basement Floor, Ramat-Aviv, Tel Aviv 69341, Israel.

Reboxetine is a selective norepinephrine reuptake inhibitor. OBJECTIVES: To evaluate the antienuretic effect of reboxetine in children with attention deficit and mood disorders. METHODS: Six children aged 12-15 years with primary nocturnal enuresis and with attention deficit/hyperactivity disorder with or without other comorbid disorders were treated with reboxetine (4-8 mg/day). Monitoring of enuretic frequency was recorded at baseline and once a week for 6 weeks. RESULTS: A statistically significant decrease in bedwetting was noted along the assessment points (p < 0.001), with the maximal change noted in the first week of treatment (p = 0.004). Reboxetine was well tolerated with minimal and transient side effects. CONCLUSIONS: reboxetine may possess an antienuretic effect in some children with the attention deficit/hyperactivity disorder.

Published 8 June 2005 in Neuropsychobiology, 51(4): 239-42.
Full-text of this article is available online (may require subscription).

© 2004-2008 ADHD Research Today. All Rights Reserved.